1312478-91-3Relevant academic research and scientific papers
Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious Gram-negative infections
Montgomery, Justin I.,Brown, Matthew F.,Reilly, Usa,Price, Loren M.,Abramite, Joseph A.,Arcari, Joel,Barham, Rose,Che, Ye,Chen, Jinshan Michael,Chung, Seung Won,Collantes, Elizabeth M.,Desbonnet, Charlene,Doroski, Matthew,Doty, Jonathan,Engtrakul, Juntyma J.,Harris, Thomas M.,Huband, Michael,Knafels, John D.,Leach, Karen L.,Liu, Shenping,Marfat, Anthony,McAllister, Laura,McElroy, Eric,Menard, Carol A.,Mitton-Fry, Mark,Mullins, Lisa,Noe, Mark C.,O'Donnell, John,Oliver, Robert,Penzien, Joseph,Plummer, Mark,Shanmugasundaram, Veerabahu,Thoma, Christy,Tomaras, Andrew P.,Uccello, Daniel P.,Vaz, Alfin,Wishka, Donn G.
, p. 1662 - 1670 (2012/04/17)
The synthesis and biological activity of a new series of LpxC inhibitors represented by pyridone methylsulfone hydroxamate 2a is presented. Members of this series have improved solubility and free fraction when compared to compounds in the previously described biphenyl methylsulfone hydroxamate series, and they maintain superior Gram-negative antibacterial activity to comparator agents.
N-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS
-
Page/Page column 59-60, (2011/07/07)
The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections. Formula (I).
